In this regard, MLL2/KMT2D and MLL3/KMT2C complexes are required to maintain H3K4me1 levels in enhancers (Rao and Dou, 2015; Sze and Shilatifard, 2016), thereby modulating enhancer activities during development and in cancer. The gene discussed is KMT2D; the disease is cancer.